News Home

Is it Time to Dump AtriCure Inc. (ATRC) Stock After it Is Lower By 0.96% in a Week?

Wednesday, August 17, 2022 03:31 PM | InvestorsObserver Analysts
Is it Time to Dump AtriCure Inc. (ATRC) Stock After it Is Lower By 0.96% in a Week?

The market has been high on AtriCure Inc. (ATRC) stock recently. ATRC gets a Bullish score from InvestorsObserver Stock Sentiment Indicator.

Sentiment Score - ,bullish
AtriCure Inc. has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on ATRC!

What is Stock Sentiment?

In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company. Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor. InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon. The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.

What's Happening With ATRC Stock Today?

AtriCure Inc. (ATRC) stock is trading at $50.31 as of 3:30 PM on Wednesday, Aug 17, a decline of -$2.30, or -4.37% from the previous closing price of $52.61. The stock has traded between $49.93 and $52.48 so far today. Volume today is 204,548 compared to average volume of 230,428. To screen for more stocks like AtriCure Inc. click here.

More About AtriCure Inc.

AtriCure Inc is a innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation Pacing and Sensing, and others. The company also offers a variety of minimally invasive ablation devices and access tools to facilitate the growing trend in less invasive cardiac and thoracic surgery. Geographically, it generates a majority of its revenue from the United States. Click Here to get the full Stock Report for AtriCure Inc. stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App